Подготовка шейки матки к родам


Баев О.Р.

Представлен обзор литературы, посвященной оценке эффективности, безопасности, определению оптимальных доз и режимов использования, частоте побочных эффектов медикаментозных средств, используемых для подготовки шейки матки к родам. В настоящее время доказана эффективность и целесообразность применения простагландинов (ПГ) и мифепристона. Из ПГ чаще применяют аналоги ПГЕ2 или ПГЕ1. Наиболее часто используют интрацервикальный и влагалищный методы введения ПГ. ПГ для созревания шейки матки обычно применяют в стационаре, так как они могут вызвать ряд побочных эффектов. Мифепристон характеризуется как препарат, моделирующий естественные процессы созревания шейки матки и фактически не имеющий клинически значимых побочных эффектов. Допускается использование мифепристона для дородовой подготовки в амбулаторных условиях. В доступной нам научной литературе нет исследований по сравнению эффективности применения мифепристона и ПГ, а вопросы использования препаратов, стимулирующих образование оксида азота, в настоящее время остаются недостаточно изученными.

Литература


1. Ковалев В. В., Цывьян П.Б., Миляева Н.М. и др. Физиологические основы регуляции сократительной активности матки // Акушерство и гинекология. 2010. С. 10–13.
2. Le Ray C, Carayol M, Braart G, et al. PREMODA Study Group. Elective induction of labor: failure to follow guidelines and risk of cesarean delivery. Acta Obstet Gynecol Scand 2007;86(6):657–65.
3. Сидорова И.С. Физиология и патология родовой деятельности. М., 2000. 320 с.
4. Kelly AJ, Kavanagh J, Thomas J. Relaxin for cer vical ripening and induction of labour. Cochrane Database Syst Rev 2001;2:CD003103.
5. Kavanagh J, Kelly AJ, Thomas J. Hyaluronidase forcervical ripening and induction of labour. Cochrane Database Syst Rev 2006;(2):CD003097.
6. Thomas J, Kelly AJ, Kavanagh J. Oestrogens alone or with amniotomy for cervical ripening or induction of labour. Cochrane Database Syst Rev 2001;(4):CD003393.
7. Подготовка беременных к родам. Методическое пособие / под ред. Э.К. Айламазяна. СПб., 2007. 36 с
8. Luckas M, Bricker L. Intravenous prostaglandin for induction of labour. Cochrane Database Syst Rev2000;4:CD002864.
9. French L. Oral prostaglandin E2 for induction of labour. Cochrane Database Syst Rev 2001;2:CD003098.
10. Hutton EK, Mozurkewich EL. Extra-amniotic prostaglandin for induction of labour. Cochrane Database Syst Rev 2001;2:CD003092.
11. Boulvain M, Kelly A, Irion O. Intracervical prostaglandins for induction of labour. Cochrane Database Syst Rev 2008;(1):CD006971.
12. Weeks A, Alfirevic Z, Faundes A, et al. Misoprostol for induction of labor with a live fetus. Int J Gynaecol Obstet 2007;99(Suppl. 2):S194–97.
13. Kelly AJ, Malik S, Smith L, et al. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2009;4:CD003101.
14. Fekih M, Ben Zina N, Jnifen A, et al. Comparing two Prepidil gel regimens for cervical ripening before induction of labor at term: a randomized trial. J Gynecol Obstet Biol Reprod (Paris). 2009;38(4):335–40.
15. Melamed N, Ben-Haroush A, Kremer S, et al. Failure of cervical ripening with prostaglandin-E2 can it be predicted? J Matern Fetal Neonatal Med 2010;23(6):536–40.
16. Wolf SB, Sanchez-Ramos L, Kaunitz AM. Sublingual misoprostol for labor induction: a randomized clinical trial. Obstet Gynecol 2005;105(2):365–71.
17. Kipikasa JH, Adair CD, Williamson J, et al. Use of misoprostol on an outpatient basis for postdate pregnancy. Int J Gynaecol Obstet 2005;88(2):108–11.
18. Gaffaney CA, Saul LL, Rumney PJ, et al. Outpatient oral misoprostol for prolonged pregnancies: a pilot investigation. Am J Perinatol 2009;26(9):673–77.
19. Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2003;1:CD000941.
20. Austin SC, Sanchez-Ramos L, Adair CD. Labor induction with intravaginal misoprostol compared with the dinoprostone vaginal insert: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;202(6):624.e1–9.
21. Szczesny W, Sandvik L. Pre-induction cervical ripening with 25 microg and 50 microg vaginal misoprostol in 181 nulliparous parturients. J Matern Fetal Neonatal Med 2009;22(3):265–68.
22. Martinez de Tejada B, Martillotti G, Lapaire O,et al. The risk of placental abruption when using prostaglandins for cervical ripening in women with preeclampsia: comparing misoprostol versus dinoprostone. J Matern Fetal Neonatal Med 2010;23(9):988–93.
23. Dede H, Kandemir O, Yalvac S, et al. Is dinoprostone safe? A report of three maternal deaths. J Matern Fetal Neonatal Med 2010;23(6):569–72.
24. Alfirevic Z, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2006;2:CD001338.
25. Chan CC, Lao TT, Ho PC, et al. The effect of mifepristone on the expression of steroid hormone receptors in human decidua and placenta: a randomized placebo-controlled double-blind study. J Clin Endocrinol Metab 2003;88(12):5846–50.
26. Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. Contraception 2006;74(1):48–55.
27. Catalano RD, Critchley HO, Heikinheimo O, et al. Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Molecular Human Reproduction 2007;13(9):641–54.
28. Fassett MJ, Lachelin GC, McGarrigle HH, et al. Alterations in saliva steroid hormone levels after oral mifepristone administration in women with pregnancies of greater than 41 weeks’ gestation. Reprod Sci 2008;15(4):394–99.
29. Chien CH, Lai JN, Liao CF, et al. Mifepristone acts as progesterone antagonist of non-genomic responses but inhibits phytohemagglutinininduced proliferation in human T cells. Hum Reprod 2009;24(8):1968–75.
30. Perusquia M, Espinoza J, Navarrete E. Nongenomic uterine relaxing effect of RU 486 (mifepristone) prior to its antiprogesterone activity in the human pregnancy. Steroids 2009;74(10–11):825–31.
31. DeHart RM, Morehead MS. Mifepristone. Ann Pharmacother 2001;35:707–19.
32. Синчихин С.П., Мамиев О.Б., Галкина Н.Н. и др. Клиническая эффективность применения мифепристона при доношенной беременности // Акушерство и гинекология. 2009. № 5. С. 56–58.
33. Миляева Н.М., Ковалев В.В., Лебедева Л.М. Оценка эффективности и безопасности применения Мифепристона для преиндукции и индукции родов // Вопросы гинекологии, акушерства и перинатологии. 2007. Т. 6. 4. С. 18–21.
34. Gallot D, de Lapasse C, Houlle C, et al. Obstetrical prognosis of labour induction with mifepristone after 41 weeks of gestation. Article in French. Gynecol Obstet Fertil 2004;32(9):708–12.
35. McGill J, Shetty A. Mifepristone and misoprostol in the induction of labor at term. Int J Gynaecol Obstet 2007;96(2):80–84.
36. Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous cesarean section. Contraception 2006;73(3):244–48.
37. Zhonghua Fu Chan Ke Za Zhi. Induced termination of second and third trimester pregnancy in women with scarred uterus. 2010;45(1):17–21.
38. Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004;104(1):174–85.
39. Vayrynen W, Heikinheimo O, Nuutila M. Misoprostol-only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal death. Acta Obstet Gynecol Scand 2007;86(6):701–05.
40. De Heus R, Graziosi GC, Christiaens GC, et al. Medical management for termination of second and third trimester pregnancies: a comparison of strategies. Eur J Obstet Gynecol Reprod Biol 2004;116(1):16–21.
41. Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev 2009;(3):CD002865.
42. Rath WH. Outpatient induction – how safe. J Perinat Med 2009;37(5):461–67.
43. Bullarbo M, Orrskog ME, Andersch B, et al. Outpatient vaginal administration of the nitric oxide donor isosorbide mononitrate for cervical ripening and labor induction postterm: a randomized controlled study. Am J Obstet Gynecol 2007;196(1):50.e1–5.
44. Rameez MF, Goonewardene IM. Nitric oxide donor isosorbide mononitrate for pre-induction cervical ripening at 41 weeks' gestation: A randomized controlled trial. J Obstet Gynaecol Res 2007;33(4):452–56.
45. Radulovic N, Norstrom A, Ekerhovd E. Outpatient cervical ripening before first-trimester surgical
abortion: a comparison between misoprostol and isosorbide mononitrate. Acta Obstet Gynecol Scand 2007;86(3):344–48.
46. Nicoll AE, Mackenzie F, Greer IA, et al. Vaginal application of the nitric oxide donor isosorbide mononitrate for preinduction cervical ripening: a randomized controlled trial to determine effects on maternal and fetal hemodynamics. Am J Obstet Gynecol 2001;184(5):958–64.
47. Ekerhovd E, Bullarbo M, Andersch B, et al. Vaginal administration of the nitric oxide donor isosorbide mononitrate for cervical ripening at term: a randomized controlled study. Am J Obstet Gynecol. 2003;189(6):1692–97.
48. Chanrachakul B, Herabutya Y, Punyavachira P. Randomized comparison of glyceryl trinitrate and prostaglandin E2 for cervical ripening at term. Obstet Gynecol 2000;96(4):549–53.
49. Osman I, MacKenzie F, Norrie J, et al. The “PRIM” study: a randomized comparison of prostaglandin
E2 gel with the nitric oxide donor isosorbide mononitrate for cervical ripening before the induction of labor at term. Am J Obstet Gynecol 2006;194(4):1012–21.


Похожие статьи


Бионика Медиа